| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 216.46 | 8.0% | 45.4% |
| Total Income | 216.46 | 8.0% | 45.4% |
| Expenditure | 739.00 | 1.1% | 13.4% |
| PBT | 59.33 | 69.7% | 49.6% |
| Net Profit | 52.82 | 72.7% | 66.8% |
| OPM | — | ||
| NPM | 24.40% | 72.25pp | 3.12pp |
| EPS | 0.08 | 71.4% | 60.0% |
Healthpeak Properties Reports Q2 2026 Results and Increases Full Year 2026 Earnings Guidance
05 Aug 2026 · 5 Aug, 1:57 am
Summary
Healthpeak Properties announced its financial results for the second quarter ended June 30, 2026, reporting net income of $0.08 per share and FFO as Adjusted of $0.46 per share. The company also increased its full-year 2026 earnings guidance, raising diluted earnings per common share to a range of $0.48 to $0.52 and diluted FFO as Adjusted per share to $1.73 to $1.77. Key highlights include strong performance from its majority-owned subsidiary Janus Living, which saw revenue and Adjusted EBITDAre grow by 45% and 34% year-over-year, respectively, and significant proceeds generated from real estate transactions.
Key Highlights
- 1
Healthpeak Properties reported results for the quarter ended June 30, 2026, including net income of $0.08 per share and FFO as Adjusted of $0.46 per share.
- 2
Janus Living, a majority-owned subsidiary, reported year-over-year revenue and Adjusted EBITDAre growth of 45% and 34%, respectively, for the second quarter.
- 3
Total occupancy increased sequentially by 20 basis points in Outpatient Medical to 90.7% and by 80 basis points in Lab to 78.5%.
- 4
Healthpeak generated $1.4 billion of proceeds from Outpatient Medical recapitalizations, seller financing loan repayments, and dispositions during the second quarter and through August 3, 2026.
- 5
The company entered into a new $20 million outpatient medical development agreement to support Northside Hospital’s continued expansion in the Atlanta market.
- 6
Healthpeak's full year 2026 diluted earnings per common share guidance was increased to a range of $0.48 to $0.52, and diluted FFO as Adjusted per share guidance was increased to $1.73 to $1.77.
- 7
A new $500 million share repurchase program was authorized by the Board of Directors.
Management Comments
Kelvin O. Moses
The information set forth in this Item 2.02 of this Current Report on Form 8-K and the related information in Exhibits 99.1, 99.3, and 99.4 attached hereto are being furnished herewith, and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference therein. The information set forth in this Item 7.01 of this Current Report on Form 8-K and the related information in Exhibit 99.2 attached hereto is being furnished herewith, and shall not be deemed filed for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing with the Securities and Exchange Commission under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference therein.
Informational and educational content only. Not investment advice.